Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA07 MICARDIS B Telmisartan - 40mg 40mg Tablet 760,615 L.L
L01BB04 LITAK 10 B Cladribine - 10mg/5ml 10mg/5ml Injectable solution 39,016,157 L.L
L04AD01 SANDIMMUN NEORAL B Ciclosporin - 100mg/ml 100mg/ml Solution 8,264,592 L.L
N02BG06 ACUPAN B Nefopam HCl - 20mg 20mg Injectable solution 365,525 L.L
N06DX01 EBIXA B Memantine - 20mg 20mg Tablet, film coated 4,004,651 L.L
S01LA09 VABYSMO B Faricimab - 6mg/0.05ml 6mg/0.05ml Injectable solution 54,991,170 L.L
A07EA06 CORTIMENT MMX B Budesonide - 9mg 9mg Tablet, prolonged release 8,996,996 L.L
C05BB02 AETHOXYSKLEROL B Polidocanol (Lauromacrogol 400) - 1% 1% Injectable solution 1,732,213 L.L
L01BB04 MAVENCLAD B Cladribine - 10mg 10mg Tablet 182,343,396 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
S01XA18 RESTASIS B Ciclosporin - 0.5mg/ml 0.05% Emulsion 4,100,063 L.L
A07EC02 ASACOL B Mesalazine - 400mg 400mg Tablet, enteric coated 5,895,437 L.L
A10BX02 NOVONORM B Repaglinide - 0.5mg 0.5mg Tablet 475,720 L.L
C05BB02 AETHOXYSKLEROL B Polidocanol (Lauromacrogol 400) - 3% 3% Injectable solution 2,576,146 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
M03BC51 NORGESIC B Paracetamol - 450mg, Orphenadrine (citrate) - 35mg Tablet 412,560 L.L
N02BG09 PENTHROX INHALER B Methoxyflurane - Inhalation 21,080,096 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet 306,396 L.L
S01XA18 RESTASIS B Ciclosporin - 0.5mg/ml 0.05% Emulsion 4,100,063 L.L
A07EC02 SALOFALK B Mesalazine - 500mg 500mg Tablet, enteric coated 2,874,479 L.L
C05BX01 DOXIUM B Calcium dobesilate - 500mg 500mg Capsule 2,151,492 L.L
C09CA07 MICARDIS B Telmisartan - 80mg 80mg Tablet 998,475 L.L
G04CB02 AVODART B Dutasteride - 0.5mg 0.5mg Capsule 2,568,489 L.L
N02CC01 IMIGRAN B Sumatriptan (succinate) - 100mg 100mg Tablet, film coated 616,824 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet 306,396 L.L
R05CA12 PROSPAN ACUTE EFFERVESCENT COUGH TABLETS B Dried Ivy leaf extract - 65mg Tablet, effervescent 479,752 L.L
A10BX02 NOVONORM B Repaglinide - 1mg 1mg Tablet 571,133 L.L
C05BX01 DOXIUM B Calcium dobesilate - 500mg 500mg Capsule 1,323,685 L.L
J01XX01 MONUROL B Fosfomycine (trométamol) - 3g 3g Granules for solution 571,133 L.L
L01BB06 EVOLTRA B Clofarabine - 1mg/ml 1mg/ml Injectable concentrate for solution 91,416,937 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025